Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy

Stroke

Volumn 43, Issue 4, 2012, Pages 952-957

  Rossouw, Jacques E ^a   Johnson, Karen C ^b   Pettinger, Mary ^c   Cushman, Mary ^d   Sandset, Per Morten ^e   Kuller, Lewis ^f   Rosendaal, Frits ^g   Rosing, Jan ^h   Wasserthal Smoller, Sylvia ⁱ   Martin, Lisa W ^j   Manson, Joann E ^k   Lakshminarayan, Kamakshi ^l   Merino, Jose G ^m   Lynch, John ^m  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c USA   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MAASTRICHT UNIVERSITY   (Netherlands)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

more..

Author keywords

cerebrovascular accident; estrogen; hemostasis; menopause; randomized controlled trials

Indexed keywords

TISSUE FACTOR PATHWAY INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AFRICAN AMERICAN; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BRAIN ISCHEMIA; CASE CONTROL STUDY; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; EUROPEAN AMERICAN; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HORMONAL THERAPY; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

ACTIVATED PROTEIN C RESISTANCE; AGED; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS; MIDDLE AGED; POSTMENOPAUSE; PROTEIN C; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84859334210     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.643072     Document Type: Article

References (27)

1. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: A randomized trial. JAMA. 2003;289:2673-2684 (Pubitemid 37430138)
2. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434 (Pubitemid 43948050)
3. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, et al. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials. 2007;2:e28
4. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573-1580 (Pubitemid 39314963)
5. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-780
6. Per Morten Sandset, Hoibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thrombosis Research. 2009; 123(suppl E):S70-S73
7. Hoibraaten E, Qvigstad, Andersen TO, Mowinckel M-C, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind clinical trial. Thromb Haemost. 2001;85:773-781
8. Hoibraaten E, Mowinckel M-C, De Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001;115:415-420 (Pubitemid 34203511)
9. Curvers J, Thomassen MCLGD, Nicolaes GAF, Van Oerle R, Hamulyak K, Hemker HC, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105:88-94 (Pubitemid 29197147)
10. Van Vliet HAAM, Bertina RM, Dahm AEA, Rosendaal FR, Rosing J, Sandset PM, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor inhibitor. J Thromb Haemost. 2008;6:346-351
11. Duering C, Kosch A, Langer C, Thedieck S, Nowak-Gottl U. Total tissue factor pathway inhibitor is an independent risk factor for pediatric venous thromboembolism and stroke. Thromb Haemost. 2004;92:701-712
12. Abumiya T, Yamaguchi T, Terasaki T, Kowakawa T, Kario K, Kato H. Decreased plasma tissue factor inhibitor activity in ischemic stroke patients. Thromb Haemost. 1995;74:1050-1054
13. Zunker P, Hohenstein C, Plendl H-J, Zeller JA, Caso V, Georgiadis D, et al. Activated protein C resistance and acute ischemic stroke: relation to stroke causation and age. J Neurol. 2001;248:701-704 (Pubitemid 32695868)
14. Novo G, Caplice N, Tantillo R, Bonura F, Simari R, Novo S. TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications. Int Angiol. 2005;24:366-371 (Pubitemid 43103690)
15. Mitchell CT, Kamineni A, Palmas W, Cushman M. Tissue factor inhibitor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2009;207:277-283
16. Regnault V, Perret-Guillaume C, Kearney-Schwartz A, Max JP, Labat C, Louis H, et al. Tissue factor pathway inhibitor: A new link among arterial stiffness, pulse pressure, and coagulation in postmenopausal women. Arterioscler Thromb Vasc Biol. 2011;31:1226-1232
17. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333 (Pubitemid 34761611)
18. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701-1712
19. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41 (Pubitemid 23014379)
20. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003;101:4387-4392 (Pubitemid 36857803)
21. Ostergaard PB, Beck TC, Orsted H, Svendsen A, Nordfang O, Sandset PM, et al. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res. 1997;87:4447-4459
22. Bendz B, Andersen TO, Sandset PM. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res. 2000;97:463-472 (Pubitemid 30125713)
23. Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscl Thromb Vasc Biol. 2010;30:136-137
24. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ. 2010;340:c2519
25. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 1998;79:495-499 (Pubitemid 28120778)
26. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias and arterial stroke. Can it cause more harm than good? Stroke. 2010;41:2985-2990
27. Jackson CA, Hutchison A, Dennis MS, Wardlaw JM, Lindgren A, Norrving B, et al. Differing risk factor profiles of ischemic stroke subtypes. Evidence for a distinct lacunar arteriopathy? Stroke. 2010;41:624-629